ACE and prostate carcinoma: Our largely null findings for genetically proxied ACE inhibition and risk of breast, lung, and prostate cancer risk are not consistent with some previous observational reports that compared ACE inhibitor users to nonusers or to users of β blockers or thiazide diuretics [7,9,17].